A Study of miRNA 371 in Patients With Germ Cell Tumors

  • STATUS
    Recruiting
  • End date
    Apr 1, 2025
  • participants needed
    956
  • sponsor
    Southwest Oncology Group
Updated on 26 November 2020
Investigator
Patricia N. O'Kane, B.S.
Primary Contact
Kaiser Permanente-Walnut Creek (0.7 mi away) Contact
+271 other location
gonadotropin
cancer
beta-human chorionic gonadotropin
tumor markers
human chorionic gonadotropin
alpha fetoprotein
beta human chorionic gonadotropin
testicular
germ cell cancer

Summary

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

Description

PRIMARY OBJECTIVE:

I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy.

SECONDARY OBJECTIVES:

I. To bank prospectively obtained serial liquid biospecimens for low and moderate risk of relapse patients annotated by patient level clinical data.

II. To bank prospectively collected, clinically annotated specimens for high risk patients and non-testicular primary patients in collaboration with Children's Oncology Group study AGCT 1531.

OUTLINE

Patients undergo collection of blood every 3-6 months for up to 3 years.

Details
Treatment biomarker analysis, Blood Product Collection
Clinical Study IdentifierNCT04435756
SponsorSouthwest Oncology Group
Last Modified on26 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Germ Cell Tumors or Stage IB Testicular Cancer AJCC v8 or Metachronous Malignant Neoplasm or Stage IA Testicular Cancer AJCC v8 or Stage IS Testicular...?
Do you have any of these conditions: Germ Cell Tumors or Stage IA Testicular Cancer AJCC v8 or Stage IS Testicular Cancer AJCC v8 or Seminoma or Germ cell tumor or Metachronous Malignant ...?
Do you have any of these conditions: Germ Cell Tumors or Seminoma or Stage IB Testicular Cancer AJCC v8 or Stage IA Testicular Cancer AJCC v8 or Stage IS Testicular Cancer AJCC v8 or Meta...?
Do you have any of these conditions: Stage IB Testicular Cancer AJCC v8 or Metachronous Malignant Neoplasm or Stage I Testicular Cancer AJCC v8 or Stage IA Testicular Cancer AJCC v8 or St...?
Do you have any of these conditions: Germ Cell Tumors or Metachronous Malignant Neoplasm or Stage I Testicular Cancer AJCC v8 or Germ cell tumor or Stage IS Testicular Cancer AJCC v8 or S...?
Patients must have a new diagnosis of a germ cell tumor. confirmed pathologically or serologically (diagnostic elevation of human chorionic gonadotropin [HCG]/alpha-fetoprotein [AFP]). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible
If surgery is planned, male patients with clinical stage I testicular cancer must have orchiectomy completed within 42 days prior to registration
Patients must be registered within 42 days after diagnosis and prior to initiation of a management plan or treatment for the disease
Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected
Patients must have beta-human chorionic gonadotropin (beta- HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
NOTE: If the patient had an orchiectomy prior to registration, report tumor marker values before and after surgery on the Baseline Tumor Marker form
Patients must have risk of relapse assessment determined by the local investigator prior to registration
Patients must agree to submit required specimens for defined translational medicine studies. These specimens are drawn at the same time as standard laboratory evaluations (beta-HCG, AFP, and LDH); NOTE: Ideally, patients should be willing to return to their center performing surveillance (registering site) for the duration of the study to ensure that specimens are timed to standard clinical observations (the registering site's surveillance schedule)
Patients must be offered participation in specimen banking for future research. With patient's consent, specimens must be submitted
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet